Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$309.7M
57M shares
52-week range
$4.00 – $7.65
39% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
12.1
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
www.abeonatherapeutics.comNo one on the platform currently holds ABEO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 161,082 | $721.6K |
| Execution date | Ratio |
|---|---|
| 2022-07-05 | 1-for-25reverse |
No one on the platform has traded ABEO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -84.5% | — | — | — | ||
| Rev. Growth % | -10.3% | |||||
| Profit Margin % | 1223.1% | |||||
| Free Cash Flow Margin % | -1448.5% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $54M | +1026.3% | $-0.95 | $-1.18–$-0.51 | — | 5 |
| 2027 | $119M | +118.7% | $-0.19 | $-0.58–$0.53 | — | 4 |
| 2028 | $180M | +51.2% | $0.38 | $-0.47–$1.13 | 14.5× | 4 |
| 2029 | $281M | +56.6% | $1.45 | $0.96–$2.22 | 3.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.23 | $-0.35 | -51.1% |
| 2026-05-13 | $-0.33 | $-0.30 | +9.1% |
| 2026-03-17 | $-0.35 | $-0.34 | +2.9% |
| 2025-11-12 | $-0.27 | $-0.10 | +63.0% |
| 2025-08-11 | $-0.39 | $1.71 | +538.5% |
| 2025-05-14 | $-0.35 | $-0.24 | +31.4% |
| 2025-03-20 | $-0.35 | $-0.24 | +31.0% |
| 2024-11-14 | $-0.38 |
| $-0.63 |
| -65.8% |
| -1.36% |
| $256M |
| — |
| HUMAHumacyte, Inc. | $0.56 | -1.16% | $94M | — |
| PBYIPuma Biotechnology, Inc. | $9.14 | +0.22% | $465M | — |
Source: Financial Modeling Prep · peers by sector/industry
$ABEO I'm thinking that the portion of the$30 mill which will kick in upon fda approval of UX-111 this week will probably be recognized as ABEO revenue in this month (ie Q3) regardless of when the cash is actually received. Hence I think that this milestone revenue, combined with Zevaskyn revenue, will probably result in a profit in Q3 for Abeona. I like that very much!
View on StockTwits ↗
$ABEO Dystrophic Epidermolysis Bullosa Market Insight, Epidemiology, and Market Forecast to 2036 The "Dystrophic Epidermolysis Bullosa (DEB) - Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of the DEB treatment landscape, patient population, competitive environment, and commercial outlook across the United States, EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan. The dystrophic epidermolysis bullosa market is projected to expand at a compound annual growth rate of approximately 7% from 2026 to 2036. Growth is expected to be driven by the introduction of gene and cell therapies, continued pipeline development, increasing investment in rare disease research, and favorable regulatory pathways for innovative treatments.
View on StockTwits ↗$ABEO - starts to stretch..... (Happy Happy Dance time)
View on StockTwits ↗
$ABEO https://www.facebook.com/story.php?story_fbid=1504897878336498&id=SavingSadieRae Waited long enough. A special message to the FDA.
View on StockTwits ↗$ABEO TLX - FDA decision was yesterday but still no news yet. Totally different product but they also had crl on their first try like our partner RARE did. Let's hope it comes before the 19th but if it doesn't it's more than likely I'll come the fellowing week. ABEO is also listed on the FDA calendar for UX111 decision on 19th.
View on StockTwits ↗$ABEO JUST 6 PROCEDURES per month would amount to $18M per month in revenues or a total of $216M per year. With a current Market Cap of just $309M, it would mean that currently ABEO is selling for a p/s ratio of just 1.43. And with Gross Margins expected of about 85% the share price is amazingly under valued. Here's what Ai thinks about that: "Based on the metrics provided, the stock appears heavily undervalued on a relative basis (https://www.investopedia.com/articles/fundamental/03/032603.asp) A high gross margin of 85% is typical of software or biotech companies. These industries usually command much higher Price-to-Sales (P/S) multiples—often between 5x and 15x—because their high gross margins allow a massive percentage of revenue to flow down to net profits as the company scales. Paying just 1.4x revenue for an 85% gross margin business is incredibly cheap. [1] "
View on StockTwits ↗$ABEO Abeona at Cantor healthcare conference: slow launch, big rare-disease bet Key takeaways ZEVASKYN has moved from clinical development into commercial use, with about a dozen patients treated and 7 qualified treatment centers active. Abeona said it has secured coverage for more than 95% of commercial lives, baseline Medicaid coverage in all 51 jurisdictions and no ultimate denials so far. Manufacturing currently supports 6 slots per month, and the company is working toward 10 slots monthly by 2027. Management described 2026 and early 2027 as foundational years focused on site activation, patient education and operational scale-up. Partnered programs, including UX111, Taysha’s Rett syndrome work and Beacon Therapeutics, may add value with limited R&D burden on Abeona. https://www.investing.com/news/transcripts/abeona-at-cantor-healthcare-conference-slow-launch-big-raredisease-bet-93CH-4893614
View on StockTwits ↗
$ABEO Listened to the Cantor Q&A no new info though more questions about RARE’s UX111 and the related royalties and the prostrate drug going into clinical trials. Two more investment conf coming up. Been here awhlie as a long and seeing good things down the road.
View on StockTwits ↗
$ABEO Moved south of the 200DMA on higher volume. RSI=33.74... moving closer to oversold territory.
View on StockTwits ↗
$ABEO - Whoo hoo! Caught another lot at $5.34! - goal is to get to 10k shares! Happy Happy times!
View on StockTwits ↗
$ABEO Can we get a C-suite that isn't comprised of taxi drivers?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.